medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2012, Number 3

<< Back Next >>

Acta Ortop Mex 2012; 26 (3)

Fibrodysplasia ossificans progressiva. A case report

Díaz-de la Torre J

Language: Spanish
References: 22
Page: 192-196
PDF size: 128.01 Kb.


ABSTRACT

Fibrodysplasia ossificans progressiva (FOP) is characterized by the progressive heterotopic ossification of connective tissue. The case we report herein is a female, 10 year-old patient with the clinical and radiologic characteristics of FOP. Upon birth she had toe deformities; during childhood she had limitation of neck rotation, and at 4 years of age she had swelling of the right scapular region and a biopsy was taken. She then had induration and calcification of the surgical site. She currently has cervical spine stiffness and multiple bone masses on the scapulas, the left axillary fold, the vertebral region and the iliac crest. Molecular studies were done with sequencing of the ACVR1 gene. Mutation p.Arg206His, a mutation associated with FOP, was found; it is the most frequent mutation found in this condition. The little knowledge that physicians have about this condition lead to missed diagnoses or improper management. Estimates show that there is one case per 2 million live births. The purpose of this study is to publish one more case, confirmed clinically, radiologically, and with molecular tests.


REFERENCES

  1. Kaplan FS, et al: The phenotype of fibrodisplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005; 3: 183-8.

  2. Cohen RB, et al: The natural history of heterotopic ossification in patients who have fibrodisplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 1993; 75: 215-9.

  3. Connor JM, Evans DA: Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br 1982; 64: 76-83.

  4. Glaser DL, et al: In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003; 85-A: 2332–42.

  5. Kaplan FS, et al: The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Joint Surg Am 1993; 75: 220–30.

  6. Shore EM, et al: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006; 38: 525–7.

  7. Kaplan FS, Glaser DL, Pignolo RJ, Shore EM: A new era for fibrodysplasia ossificans progressiva: A druggable target for the second skeleton. Expert Opin Biol Ther 2007; 7: 705-12.

  8. Kaplan FS, Le MM, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM: Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 2008; 22: 191-205.

  9. Delatycki M, Rogers JG: The genetics of fybrodisplasia ossificans progressiva. Clin Orthop 1998; 346: 15-8.

  10. Qi Shen, Shawn CL: The fibrodysplasia ossificans progressive R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. The Journal of Clinical Investigation 2009; 119: 3462-72.

  11. Goncalves AL, Masruha MR, de Campos CC, Delai PL, Vilanova LC. Fibrodysplasia ossificans progresiva. Case report. Arq Neuropsiquiatr 2005; 63: 1090-3.

  12. Alaani A, Hogg R, Warfield AT, Olliff J, Jennings C. Air bag injury as a cause of inflammatory myofibroblastic pseudotumour of the subglottic larynx progressing to myositis ossificans. Acta Otolaryngol 2005; 125: 674-7.

  13. Kaplan FS, Shore EM, Glaser DL, Emerson S and the International Clinical Consortium of Fibrodysplasia Ossificans Progressiva: The medical management of fibrodysplasia ossificans progressiva: Current treatment considerations. Clin Proc Intl Clin Consort FOP 2003; 2: 1-72.

  14. Feldman G, Li M, Martin S, Urbanek M, Urtizberea JA, Fardeau M, LeMerrer M, Connor JM, Triffitt J, Smith R, Muenke M, Kaplan FS, Shore EM: Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet 2000; 66: 128–35.

  15. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 1996; 335: 555-61.

  16. Goncalves AL, Masruha MR, de Campos CC, Delai PL, Vilanova LC: Fibrodysplasia ossificans progresiva. Case report. Arq Neuropsiquiatr 2005; 63: 1090-3.

  17. Magryta CJ, Kligora CJ, Temple HT, Malik RK: Clinical presentation of fibrodysplasia ossificans progressiva: pitfalls in diagnosis. J Pediatr Hematol Oncol 1999; 21: 539-43.

  18. Blaszczyk M, Majewski S, Brzezinska-Wcislo L, Jablonska S: Fibrodysplasia ossificans progressiva. Eur J Dermatol 2003; 13: 234-7.

  19. Bridges AJ, Hsu KC, Singh A, Churchill R, Miles J: Fibrodysplasia (Myositis) ossificans progressive. Semin Arthritis Rheumat 1994; 24: 155-64.

  20. Lindhout D, Golding RP Taets van Amerongen AHM. Fibrodysplasia ossificans progressiva: current concepts and the role of CT in acute changes. Pediatric Radiol 1985; 15: 211-3.

  21. Osmanagaoglu K, Kuyvenhoven J, Dierckx RA, Hamers J, Cuvelier C, Uyttendaele D, Simons M. Thallium-201 accumulation in myositis ossificans and in juxta-articular ossification. J Nucl Med 1995; 36: 2239-42.

  22. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010; 92: 686-91.




2020     |     www.medigraphic.com